The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

NCT03927352 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: SCT630
BIOLOGICAL: Adalimumab

Sponsor

Sinocelltech Ltd.